The cholesterol controversy

被引:11
作者
Geurian, KL
机构
[1] Department of Pharmacy Practice, Univ. of Arkansas for Med. Sciences, Little Rock, AR 72205
关键词
D O I
10.1177/106002809603000512
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To provide information about the controversy associated with lowering of cholesterol concentrations to prevent coronary heart disease (CHD). DATA SOURCES: Studies, review articles, and editorials identified from MEDLINE searches (from 1966 to 1995) and bibliographies of identified articles. STUDY SELECTION: Studies, review articles, and editorials addressing controversial issues related to cholesterol lowering. DATA EXTRACTION: Pertinent information was selected and the data synthesized into a review format. DATA SYNTHESIS: Hypercholesterolemia is a well-known CHD risk factor. Reduction of serum cholesterol concentrations has been shown to reduce the incidence of CHD. Unfortunately, cholesterol lowering also appears to increase the risk for cancer, accidental and violent death, stroke, and oddly enough, CHD when certain medications are used. CONCLUSIONS: Significant reductions in serum cholesterol concentrations can be achieved with cholesterol-lowering interventions. However, the benefits associated with cholesterol reduction may not outweigh the risks in all patients with hypercholesterolemia. Cholesterol-lowering interventions should be recommended with caution in patients at increased risk for cancer, stroke, and depression. Caution should also be used when recommending fibric acid derivatives for patients with existing CHD.
引用
收藏
页码:495 / 500
页数:6
相关论文
共 60 条
  • [1] *AM HEART ASS, 1992, 1992 HEART STROK FAC, P199
  • [2] [Anonymous], 1965, LANCET, V2, P501
  • [3] CHOLESTEROL REDUCTION AND THE RISK FOR STROKE IN MEN - A METAANALYSIS OF RANDOMIZED, CONTROLLED TRIALS
    ATKINS, D
    PSATY, BM
    KOEPSELL, TD
    LONGSTRETH, WT
    LARSON, EB
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (02) : 136 - 145
  • [4] BARRADAS MA, 1992, LANCET, V339, P1168, DOI 10.1016/0140-6736(92)90768-X
  • [5] CORONARY ANGIOGRAPHIC CHANGES WITH LOVASTATIN THERAPY - THE MONITORED ATHEROSCLEROSIS REGRESSION STUDY (MARS)
    BLANKENHORN, DH
    AZEN, SP
    KRAMSCH, DM
    MACK, WJ
    CASHINHEMPHILL, L
    HODIS, HN
    DEBOER, LWV
    MAHRER, PR
    MASTELLER, MJ
    VAILAS, LI
    ALAUPOVIC, P
    HIRSCH, LJ
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) : 969 - 976
  • [6] BENEFICIAL-EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS
    BLANKENHORN, DH
    NESSIM, SA
    JOHNSON, RL
    SANMARCO, ME
    AZEN, SP
    CASHINHEMPHILL, L
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (23): : 3233 - 3240
  • [7] EXPANDED CLINICAL-EVALUATION OF LOVASTATIN (EXCEL) STUDY RESULTS .1. EFFICACY IN MODIFYING PLASMA-LIPOPROTEINS AND ADVERSE EVENT PROFILE IN 8245 PATIENTS WITH MODERATE HYPERCHOLESTEROLEMIA
    BRADFORD, RH
    SHEAR, CL
    CHREMOS, AN
    DUJOVNE, C
    DOWNTON, M
    FRANKLIN, FA
    GOULD, AL
    HESNEY, M
    HIGGINS, J
    HURLEY, DP
    LANGENDORFER, A
    NASH, DT
    POOL, JL
    SCHNAPER, H
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1991, 151 (01) : 43 - 49
  • [8] EFFECTS OF THERAPY WITH CHOLESTYRAMINE ON PROGRESSION OF CORONARY ARTERIOSCLEROSIS - RESULTS OF THE NHLBI TYPE-II CORONARY INTERVENTION STUDY
    BRENSIKE, JF
    LEVY, RI
    KELSEY, SF
    PASSAMANI, ER
    RICHARDSON, JM
    LOH, IK
    STONE, NJ
    ALDRICH, RF
    BATTAGLINI, JW
    MORIARTY, DJ
    FISHER, MR
    FRIEDMAN, L
    FRIEDEWALD, W
    DETRE, KM
    EPSTEIN, SE
    [J]. CIRCULATION, 1984, 69 (02) : 313 - 324
  • [9] ETHICAL ISSUES IN RISK FACTOR INTERVENTION
    BRETT, AS
    [J]. AMERICAN JOURNAL OF MEDICINE, 1984, 76 (04) : 557 - 561
  • [10] PSYCHOLOGIC EFFECTS OF THE DIAGNOSIS AND TREATMENT OF HYPERCHOLESTEROLEMIA - LESSONS FROM CASE-STUDIES
    BRETT, AS
    [J]. AMERICAN JOURNAL OF MEDICINE, 1991, 91 (06) : 642 - 647